Skip to main content

Advertisement

SpringerLink
Log in

GDF-15: a novel serum marker for metastases in uveal melanoma patients

  • Oncology
  • Published:
Graefe's Archive for Clinical and Experimental Ophthalmology Aims and scope Submit manuscript

Abstract

Background

About 50% of patients with uveal melanoma (UM) develop metastases during the course of their disease. We analyzed serum levels of Growth Differentiation Factor-15 (GDF-15), with the aim of identifying patients with early metastases.

Methods

GDF-15 concentration was measured using an enzyme-linked immunosorbent assay (ELISA) in serum samples from 188 UM patients (170 patients without metastases; 18 patients with clinically detectable metastases) and 18 healthy control individuals. Data were analyzed with respect to differences between patients with and without clinically detectable UM metastases. GDF-15 serum levels were further analyzed with regard to significant patient and tumor characteristics as revealed by histology and multiplex ligation-dependent probe amplification (MLPA) to determine chromosome 3 copy number. GDF-15 expression in UM was investigated by immunohistochemistry.

Results

Patients with clinically detectable metastases had significantly higher GDF-15 serum levels compared to those without clinically detectable metastases as well as to healthy individuals (ANOVA; p < 0.001). GDF-15 concentrations in UM patients with overt clinically detectable metastases were significantly higher than those in UM patients with a second malignancy in remission but without clinically detected UM metastases (ANOVA; p < 0.001). No association between serum concentration of GDF-15 and clinical, pathological, and genetic features was observed. GDF-15 protein was only expressed in a minority of UM cells in most tumors.

Conclusions

Our data suggest that GDF-15 can be used as a serum marker for the diagnosis of metastases in UM patients. Further data collection and analysis are necessary to evaluate a possible prognostic role of GDF-15 in predicting early metastases.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

References

  1. Singh AD, Topham A (2003) Incidence of uveal melanoma in the United States: 1973–1997. Ophthalmology 110:956–961

    Article  PubMed  Google Scholar 

  2. Shields CL, Shields JA, Cater J, Lois N, Edelstein C, Gündüz K, Mercado G (1998) Transpupillary thermotherapy for choroidal melanoma. Tumor control and visual results in 100 consecutive cases. Ophthalmology 105:581–590

    Article  PubMed  CAS  Google Scholar 

  3. Gragoudas E, Li W, Goitein M, Lane AM, Munzenrider JE, Egan KM (2002) Evidence-based estimates of outcome in patients irradiated for intraocular melanoma. Arch Ophthalmol 120:1665–1671

    PubMed  Google Scholar 

  4. Damato B, Groenewald C, McGalliard J, Wong D (1998) Endoresection of choroidal melanoma. Br J Ophthalmol 82:213–218

    Article  PubMed  CAS  Google Scholar 

  5. Verschueren KM, Creutzberg CL, Schalij-Delfos NE, Ketelaars M, Klijsen FL, Haeseker BI, Ligtenberg SM, Keunen JE, Marijnen CA (2010) Long-term outcomes of eye-conserving treatment with Ruthenium(106) brachytherapy for choroidal melanoma. Radiother Oncol 95:332–338

    Article  PubMed  Google Scholar 

  6. COMS report no. 15 (2001) Assessment of metastatic disease status at death in 435 patients with large choroidal melanoma in the Collaborative Ocular Melanoma Study (COMS). Arch Ophthalmol 119:670–676

    Google Scholar 

  7. Seddon JM, Albert DM, Lavin PT, Robinson N (1983) A prognostic factor study of disease-free interval and survival following enucleation for uveal melanoma. Arch Ophthalmol 101:1894–1899

    Article  PubMed  CAS  Google Scholar 

  8. Mooy CM, De Jong PT (1996) Prognostic parameters in uveal melanoma: a review. Surv Ophthalmol 41:215–228

    Article  PubMed  CAS  Google Scholar 

  9. Folberg R, Rummelt V, Parys-Van Ginderdeuren R, Hwang T, Woolson RF, Peér J, Gruman LM (1993) The prognostic value of tumor blood vessel morphology in primary uveal melanoma. Ophthalmology 100:1389–1398

    PubMed  CAS  Google Scholar 

  10. Prescher G, Bornfeld N, Hirche H, Horsthemke B, Jockel KH, Becher R (1996) Prognostic implications of monosomy 3 in uveal melanoma. Lancet 347:1222–1225

    Article  PubMed  CAS  Google Scholar 

  11. Onken MD, Worley LA, Ehlers JP, Harbour JW (2004) Gene expression profiling in uveal melanoma reveals two molecular classes and predicts metastatic death. Cancer Res 64:7205–7209

    Article  PubMed  CAS  Google Scholar 

  12. Damato B, Duke C, Coupland SE, Hiscott P, Smith PA, Campbell I, Douglas A, Howard P (2007) Cytogenetics of uveal melanoma: a 7-year clinical experience. Ophthalmology 114:1925–1931

    Article  PubMed  Google Scholar 

  13. Triozzi PL, Eng C, Singh AD (2008) Targeted therapy for uveal melanoma. Cancer Treat Rev 34:247–258

    Article  PubMed  CAS  Google Scholar 

  14. Eskelin S, Pyrhonen S, Summanen P, Prause JU, Kivela T (1999) Screening for metastatic malignant melanoma of the uvea revisited. Cancer 85:1151–1159

    Article  PubMed  CAS  Google Scholar 

  15. Hicks C, Foss AJE, Hungerford JL (1998) Predictive power of screening tests for metastasis in uveal melanoma. Eye 12:945–948

    Article  PubMed  Google Scholar 

  16. Bootcov M, Bauskin AR, Valenzuela SM, Moore AG, Bansal M, He XY, Zhang HP, Donnellan M, Mahler S, Pryor K, Walsh BJ, Nicholson RC, Fairlie WD, Por SB, Robbins JM, Breit SN (1997) MIC-1, a novel macrophage inhibitory cytokine, is a divergent member of the TGF-β superfamily. PNAS 94:11514–11519

    Article  PubMed  CAS  Google Scholar 

  17. Bauskin AR, Brown DA, Kuffner T, Johnen H, Luo XW, Hunter M, Breit SN (2006) Role of macrophage inhibitory cytokine-1 in tumorigenesis and diagnosis of cancer. Cancer Res 66:4983–4986

    Article  PubMed  CAS  Google Scholar 

  18. Welsh JB, Sapinoso LM, Kern SG, Brown DA, Liu T, Bauskin AR, Ward RL, Hawkins NJ, Quinn DI, Russell PJ, Sutherland RL, Breit SN, Moskaluk CA, Frierson HF Jr, Hampton GM (2003) Large-scale delineation of secreted protein biomarkers overexpressed in cancer tissue and serum. PNAS 100:3410–3415

    Article  PubMed  CAS  Google Scholar 

  19. Boyle GM, Pedley J, Martyn AC, Banducci KJ, Strutton GM, Brown DA, Breit SN, Parsons PG (2009) Macrophage inhibitory cytokine-1 is overexpressed in malignant melanoma and is associated with tumorigenicity. J Invest Dermatol 129:383–391

    Article  PubMed  CAS  Google Scholar 

  20. Damato B, Dopierala J, Klaasen A, van Dijk M, Sibbring J, Coupland SE (2009) Multiplex ligation-dependent probe amplification of uveal melanoma: correlation with metastatic death. Invest Ophthalmol Vis Sci 50:3048–3055

    Article  PubMed  Google Scholar 

  21. Malignant melanoma of the uvea, Edge SB, Byrd DR, Compton CC, Fritz AG, Green FL, Trotti A (eds) (2010) AJCC Cancer Staging Manual, 7th edn. Springer, New York, Dordrecht, Heidelberg, London, pp 547–560

    Google Scholar 

  22. Schaller UC, Bosserhoff A-K, Neubauer AS, Buettner R, Kampik A, Mueller AJ (2002) Melanoma inhibitory activity: a novel serum marker for uveal melanoma. Melanoma Res 12:593–599

    Article  PubMed  CAS  Google Scholar 

  23. Reiniger IW, Schaller UC, Haritoglou C, Hein R, Bosserhoff AK, Kampik A, Mueller AJ (2005) "Melanoma inhibitory activity" (MIA): a promising serological tumour marker in metastatic uveal melanoma. Graefes Arch Clin Exp Ophthalmol 243:1161–1166

    Article  PubMed  CAS  Google Scholar 

  24. Kadkol SS, Lin AY, Barak V, Kalickman I, Leach L, Valyi-Nagy K, Majumdar D, Setty S, Maniotis AJ, Folberg R, Pe'er J (2006) Osteopontin expression and serum levels in metastatic uveal melanoma: a pilot study. Invest Ophthalmol Vis Sci 47:802–806

    Article  PubMed  Google Scholar 

  25. Reiniger IW, Wolf A, Welge-Lüssen U, Mueller AJ, Kampik A, Schaller UC (2007) Osteopontin as a serologic marker for metastatic uveal melanoma: results of a pilot study. Am J Ophthalmol 143:705–707

    Article  PubMed  CAS  Google Scholar 

  26. Barak V, Frenkel S, Kalickman I, Maniotis A, Folberg R, Péer J (2007) Serum markers to detect metastatic uveal melanoma. Anticancer Res 27:1897–1900

    PubMed  CAS  Google Scholar 

  27. Koopmann J, Buckhaults P, Brown DA, Zahurak ML, Sato N, Fukushima N, Sokoll LJ, Chan DW, Yeo CJ, Hruban RH, Breit SN, Kinzler KW, Vogelstein B, Goggins M (2004) Serum macrophage inhibitory cytokine 1 as a marker of pancreatic and other periampullary cancers. Clin Cancer Res 10:2386–2392

    Article  PubMed  CAS  Google Scholar 

  28. Liu T, Bauskin AR, Zaunders J, Brown DA, Pankhurst S, Russell PJ, Breit SN (2003) MIC-1 reduces cell adhesion and induces apoptosis in prostate cancer cells. Cancer Res 63:5034–5040

    PubMed  CAS  Google Scholar 

  29. Brown DA, Ward RL, Buckhaults P, Liu T, Romans KE, Hawkins NJ, Bauskin AR, Kinzler KW, Vogelstein B, Breit SN (2003) MIC-1 serum level and genotype: associations with progress and prognosis of colorectal carcinoma. Clin Cancer Res 9:2642–2650

    PubMed  CAS  Google Scholar 

  30. Kaiserman I, Amer R, Péer J (2004) Liver function tests in metastatic uveal melanoma. Am J Ophthalmol 137:236–243

    Article  PubMed  Google Scholar 

  31. Li PX, Wong J, Ayed A, Ngo D, Brade AM, Arrowsmith C, Austin RC, Klamut HJ (2000) Placental transforming growth factor-beta is a downstream mediator of the growth arrest and apoptotic response of tumor cells to DNA damage and p53 overexpression. J Biol Chem 75:20127–20135

    Article  Google Scholar 

  32. Baek SJ, Kim KS, Nixon JB, Wilson LC, Eling TE (2001) Cyclooxygenase inhibitors regulate the expression of a TGF-beta superfamily member that has proapoptotic and antitumorigenic activities. Mol Pharmacol 59:901–908

    PubMed  CAS  Google Scholar 

  33. Ferrari N, Pfeffer U, Dell´Eva R, Ambrosini C, Noonan DM, Albini A (2005) The transforming growth factor-beta family members bone morphogenetic protein-2 and macrophage inhibitory cytokine-1 as mediators of the antiangiogenic activity of N-(4-hydroxyphenyl) retinamide. Clin Cancer Res 11:4610–4619

    Article  PubMed  CAS  Google Scholar 

  34. Graichen R, Liu D, Sun Y, Lee KO, Lobie PE (2002) Autocrine human growth hormone inhibits placental transforming growth factor-beta gene transcription to prevent apoptosis and allows cell cycle progression of human mammary carcinoma cells. J Biol Chem 277:26662–26672

    Article  PubMed  CAS  Google Scholar 

  35. Lee DH, Yang Y, Lee SJ, Kim KY, Koo TH, Shin SM, Song KS, Lee YH, Kim YJ, Lee JJ, Choi I, Lee JH (2003) Macrophage inhibitory cytokine-1 induces the invasiveness of gastric cancer cells by up-regulating the urokinase-type plasminogen activator system. Cancer Res 63:4648–4655

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Ophthalmology, Eberhard-Karls University Tuebingen, Schleichstr. 12-16, 72076, Tuebingen, Germany

    Daniela Suesskind, Andreas Schatz, Sven Schnichels, Bernd Wissinger, Karl U. Bartz-Schmidt & Sigrid Henke-Fahle

  2. Molecular and Clinical Cancer Medicine, Institute of Translational Medicine, University of Liverpool, Liverpool, UK

    Sarah E. Coupland & Sarah L. Lake

Authors
  1. Daniela Suesskind
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Andreas Schatz
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sven Schnichels
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Sarah E. Coupland
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Sarah L. Lake
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Bernd Wissinger
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Karl U. Bartz-Schmidt
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Sigrid Henke-Fahle
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Daniela Suesskind.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Suesskind, D., Schatz, A., Schnichels, S. et al. GDF-15: a novel serum marker for metastases in uveal melanoma patients. Graefes Arch Clin Exp Ophthalmol 250, 887–895 (2012). https://doi.org/10.1007/s00417-011-1786-6

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00417-011-1786-6

Keywords

Search

Navigation